---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-148777"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:47:52.054466+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IDEAYA enters clinical collaboration with AstraZeneca for IDE849 + Imfinzi in SCLC

## Summary
- Collaboration to evaluate IDE849 (DLL3 TOP1 ADC) plus AstraZeneca's Imfinzi in extensive-stage SCLC.
- IDEAYA sponsors the combination study; AstraZeneca supplies Imfinzi.
- IDE849 Phase 1 global trial ongoing in DLL3-upregulated solid tumors including SCLC, NECs, NETs, melanoma.
- No financial terms of the collaboration disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-26-148777
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312526148777/0001193125-26-148777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312526148777/d100891d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-148777
- JSON: https://secwatch.observer/filing/0001193125-26-148777.json
- Plain text: https://secwatch.observer/filing/0001193125-26-148777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.